Apogee Technology, Inc. Reports Completion of In Vivo Proof-of-Concept Studies and Filing of U.S. Patent Application

Published: Apr 30, 2008

NORWOOD, MA--(Marketwire - April 30, 2008) - Apogee Technology, Inc. (OTCBB: ATCS) (the "Company"), which is developing PyraDerm™, a proprietary intradermal drug delivery system for vaccines and other pharmaceuticals, and IntellaPAL™, a proprietary sensor based health monitoring system for the elderly care market, today reported the completion of in vivo proof-of-concept studies and the filing of a new U.S. patent application relating to its intradermal drug delivery technology. The patent application encompasses formulations and compounds that can be instrumental in the development of efficient intradermal vaccines.

Back to news